Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Sell
42
PFE Quote, Financials, Valuation and Earnings
Last price:
$26.30
Seasonality move
:
2.6%
Day range:
$26.22 - $26.56
52-week range:
$24.48 - $31.54
Dividend yield:
6.39%
P/E ratio:
35.54x
P/S ratio:
2.52x
P/B ratio:
1.62x
Volume:
35.1M
Avg. volume:
39.4M
1-year change:
-6.57%
Market cap:
$149B
Revenue:
$58.5B
EPS (TTM):
$0.74
Analysts' Opinion
-
Consensus RatingPfizer has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 13 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $31.18, Pfizer has an estimated upside of 18.54% from its current price of $26.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 4.94% downside risk from its current price of $26.30.
Fair Value
-
According to the consensus of 21 analysts, Pfizer has 18.54% upside to fair value with a price target of $31.18 per share.
PFE vs. S&P 500
-
Over the past 5 trading days, Pfizer has underperformed the S&P 500 by -4.36% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Pfizer does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pfizer has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Pfizer reported revenues of $17.7B.
Earnings Growth
-
Pfizer earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Pfizer reported earnings per share of $0.78.
Enterprise value:
206B
EV / Invested capital:
--
Price / LTM sales:
2.52x
EV / EBIT:
29.67x
EV / Revenue:
3.47x
PEG ratio (5yr expected):
--
EV / Free cash flow:
25.04x
Price / Operating cash flow:
18.18x
Enterprise value / EBITDA:
14.89x
Gross Profit (TTM):
$39.9B
Return On Assets:
1.94%
Net Income Margin (TTM):
7.16%
Return On Equity:
4.63%
Return On Invested Capital:
2.66%
Operating Margin:
29.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $99.9B | $69.3B | $59.4B | $13.5B | $17.7B | |
| Gross Profit | $65.4B | $42.2B | $39.9B | $4.2B | $12.4B | |
| Operating Income | $37.6B | $11.3B | $9B | -$2.9B | $5.3B | |
| EBITDA | $39.4B | $18.4B | $13.8B | -$1.1B | $7.3B | |
| Diluted EPS | $5.20 | $1.83 | $0.74 | -$0.42 | $0.78 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $47.7B | $57.9B | $70.4B | $74B | $43.2B | |
| Total Assets | $179B | $179.2B | $195.4B | $215B | $219.5B | |
| Current Liabilities | $34.2B | $41.8B | $44.3B | $31.1B | $43.2B | |
| Total Liabilities | $113.5B | $103.2B | $102.5B | $117.8B | $126.9B | |
| Total Equity | $65.5B | $76B | $92.9B | $97.2B | $92.6B | |
| Total Debt | $61.5B | $38.4B | $35.7B | $63.6B | $66.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $26.6B | $12B | $11.3B | $3.5B | $6.7B | |
| Cash From Investing | -$14B | -$25.7B | -$6.7B | $888M | -$2.1B | |
| Cash From Financing | -$13.2B | $15.6B | -$6.6B | -$3.8B | -$4.6B | |
| Free Cash Flow | $23.4B | $8.2B | $8.2B | $2.6B | $6.1B | |
PFE
Sector
Market Cap
$149B
$45.2M
Price % of 52-Week High
83.39%
46.55%
Dividend Yield
6.39%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-6.57%
-33.5%
Beta (5-Year)
0.644
0.747
Dividend yield:
6.39%
Annualized payout:
$1.64
Payout ratio:
222.18%
Growth streak:
13 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$26.62
200-day SMA
Sell
Level
$27.87
Bollinger Bands (100)
Sell
Level
26.02 - 29.12
Chaikin Money Flow
Sell
Level
-1.3B
20-day SMA
Sell
Level
$26.53
Relative Strength Index (RSI14)
Sell
Level
47.83
ADX Line
Sell
Level
19.97
Williams %R
Neutral
Level
-78.882
50-day SMA
Buy
Level
$26.15
MACD (12, 26)
Buy
Level
0.07
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Sell
Level
-4.5B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.7245)
Sell
CA Score
(Annual)
Level (-0.5823)
Buy
Beneish M-Score
(Annual)
Level (-2.4073)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (6.2864)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Stock Forecast FAQ
In the current month, PFE has received 7 Buy ratings 13 Hold ratings, and 1 Sell ratings. The PFE average analyst price target in the past 3 months is $31.18.
-
Where Will Pfizer Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pfizer share price will rise to $31.18 per share over the next 12 months.
-
What Do Analysts Say About Pfizer?
Analysts are divided on their view about Pfizer share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pfizer is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Pfizer's Price Target?
The price target for Pfizer over the next 1-year time period is forecast to be $31.18 according to 21 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 13 analysts rate the stock a Hold.
-
Is PFE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pfizer is a Hold. 13 of 21 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of PFE?
You can purchase shares of Pfizer via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pfizer shares.
-
What Is The Pfizer Share Price Today?
Pfizer was last trading at $26.30 per share. This represents the most recent stock quote for Pfizer. Yesterday, Pfizer closed at $26.30 per share.
-
How To Buy Pfizer Stock Online?
In order to purchase Pfizer stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Express Stock Going Lower?
American Express Company (NYSE:AXP) has long been a Buffett favorite…
Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 18
Quantum [QMCO] is down 15.61% over the past day.
Buy
51
QRVO alert for Jan 18
Qorvo [QRVO] is up 14.47% over the past day.
Sell
31
ATEX alert for Jan 18
Anterix [ATEX] is up 11.14% over the past day.
